San Francisco Business Times -- Cancer medicine company Jennerex Inc. signed a deal with Lee’s Pharmaceutical Holdings Ltd. for development and sales of its lead drug. San Francisco-based Jennerex is now testing that drug, JX-594, against liver and colorectal cancers. This deal gives Hong Kong-based Lee’s rights to the drug to treat various cancers in China, Hong Kong and Macau.
